

---

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re application of: Fogelman et al.

Attorney Docket No.: UCLAP013X1 /  
2002-340-1

Application No.: 10/520,207

Examiner: Russel, Jeffrey E.

Filed: December 23, 2005

Group: 1654

Title: G-TYPE PEPTIDES TO AMELIORATE  
ATHEROSCLEROSIS

Confirmation No.: 9839

---

**CERTIFICATE OF EFS-WEB TRANSMISSION**

I hereby certify that this correspondence is being transmitted electronically through EFS-WEB to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on March 9, 2009.

Signed: /Swapnali Joshi/  
Swapnali Joshi

**INFORMATION DISCLOSURE STATEMENT  
IN RESPONSE TO CORRESPONDING FOREIGN SEARCH REPORT OR  
FOREIGN OFFICE ACTION**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The reference(s) identified in the attached PTO Form 1449 (copies of non-U.S. references are attached) may be material to the examination of the above-identified patent application. These reference(s) were cited in a corresponding Australian application. A copy of the **Australian Office Action dated January 19, 2009** is enclosed herewith. These reference(s) are identified in compliance with the applicant's duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. Accordingly, the Examiner is requested to make the identified reference(s) of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that additional information (material to the examination of this application) does not exist or that the identified reference(s) constitute prior art.

**Statement under 37 CFR § 1.97(e)**

The undersigned hereby states that the reference(s) identified herewith were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement. (37 CFR 1.97(e)(1))

**Authorization for Deposit Account**

In view of the foregoing, it is respectfully submitted that no fee is due in conjunction with the filing of this Information Disclosure Statement. However, should the Commissioner determine that additional fees are required for filing the present Information Disclosure Statement, the Commissioner is hereby authorized to charge any such fees to our Deposit Account Number 504480 (Order No. UCLAP013X1).

Respectfully submitted,  
Weaver Austin Villeneuve & Sampson LLP

/Tom Hunter/

Tom Hunter  
Registration No. 38,498

P.O. Box 70250  
Oakland, CA 94612-0250